台灣臨床試驗主持人資料庫|TPIDB

2017-02-24 - 2018-12-31

Others

Completed

A 12 WEEK RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL GROUP, ACTIVE AND PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILE OF PF-06650833 IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Condition/Disease

RHEUMATOID ARTHRITIS
Test Drug

PF-06650833

Participate Sites
4Sites

Terminated3Sites

張棋楨

Taipei Medical University Hospital

黃春明

China Medical University Hospital-Taipei

未分科

2017-09-01 - 2027-03-09

Phase III

Completed

Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC

Condition/Disease

Melanoma, metastatic
Test Drug

NIVOLUMAB SINJ 100MG(1VLX10); IPILIMUMAB SINJ200MG(1VLX4)

Participate Sites
4Sites

Terminated4Sites

夏和雄

Taipei Medical University Hospital

Division of Hematology & Oncology

江起陸

Taipei Veterans General Hospital

Division of Thoracic Medicine

2018-03-10 - 2021-06-30

Phase I

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Condition/Disease

Locally Advanced or Metastatic Solid Tumors
Test Drug

ABBV-368

Participate Sites
5Sites

Terminated5Sites

李欣倫

Taipei Medical University Hospital

Division of Radiation Therapy

2018-12-27 - 2021-03-22

Phase I

A Multicenter, Open-Label Phase 1 Study of DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant Non-Small Cell Lung Cancer

Condition/Disease

Non-small Cell Lung Cancer
Test Drug

DS-1205c

Participate Sites
9Sites

Terminated7Sites

夏和雄

Taipei Medical University Hospital

李岡遠

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

未分科

2018-03-01 - 2020-05-31

Phase III

ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX

Condition/Disease

Hemophilia A or B
Test Drug

Fitusiran (ALN-AT3SC)

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

張家堯

Taipei Medical University Hospital

Division of Pediatrics

2018-06-29 - 2022-06-30

Phase II

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus

Condition/Disease

Systemic Lupus Erythematosus
Test Drug

BMS-986165

Participate Sites
8Sites

Recruiting8Sites

張棋楨

Taipei Medical University Hospital

2016-01-01 - 2016-12-31

Others

Condition/Disease
Test Drug

Participate Sites
1Sites

Terminated1Sites

劉明哲

Taipei Medical University Hospital

2018-04-25 - 2023-07-31

Phase III

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus

Condition/Disease

Systemic Lupus Erythematosus
Test Drug

Ustekinumab (STELARA)

Participate Sites
10Sites

Terminated8Sites

張棋楨

Taipei Medical University Hospital

羅淑芬

Linkou Chang Gung Medical Foundation

2016-05-04 - 2020-10-31

Phase II

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT TRIAL OF AC-201 CONTROLLED RELEASE TABLETS IN SUBJECTS WITH HEMOPHILIC ARTHROPATHY

Condition/Disease

HEMOPHILIC ARTHROPATHY
Test Drug

AC-201CR

Participate Sites
6Sites

Terminated5Sites

張家堯

Taipei Medical University Hospital

Division of Hematology & Oncology

邱世欣

Kaohsiung Municipal Gangshan Hospital

未分科

2016-02-01 - 2017-01-31

Phase I

A randomized, double-blind, placebo-controlled, single ascending dose first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CFZ533 in healthy subjects and rheumatoid arthritis patients

Condition/Disease

Rheumatoid arthritis
Test Drug

CFZ533

Participate Sites
1Sites

Terminated1Sites

劉明哲

Taipei Medical University Hospital

Division of Urology

Search Result

List